Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Precarious Elderly Patient Supported For Cancer Impact on Quality Of Life of a Domotic And Remote Assistance Approach for Elderly Patients Supported For Locally Advanced or Metastatic Cancer, Socially Isolated (PREDOMOS)

26. november 2018 opdateret af: Assistance Publique Hopitaux De Marseille

Precarious Elderly Patient Supported For Cancer Impact on Quality Of Life of a Domotic And Remote Assistance Approach for Elderly Patients Supported For Locally Advanced or Metastatic Cancer, Socially Isolated: Randomized, Comparative, Prospective Multi-Centre Study

The objective of the PREDOMOS study is to evaluate the impact of establishing a Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance (PS-DR) on the improvement of quality of life of elderly patients, isolated or at risk of isolation, treated for locally advanced or metastatic cancer.

Studieoversigt

Detaljeret beskrivelse

In France, social isolation and prevalence of cancer increases with the population ageing: it is estimated that in 2050, 1 of 2 cancers will be diagnosed in patients over than 75 years old. Meanwhile, the share of isolated elderly increased from 16 to 24% between 2010 and 2013. It is shown that socially precarious elderly have an increased risk of dying from cancer.

Among the areas of Comprehensive Geriatric Assessment (CGA), social assessment is crucial. It can be assessed by a self-administered 8 items questionnaire, derived from MOS-SS (Medical Outcomes Study Social Support Survey) and validated in the elderly supported for cancer: m-MOS-SS (modified Medical Outcomes Study Social Support).

Once spotted, social isolation can be averted by appropriate measures, provided the intervention of a multidisciplinary team. In this area, the techniques of automation and remote assistance might have an interest. They already demonstrated their impact on falls prevention, addiction, feelings of social isolation and quality of life. However, little is known about the impact of social isolation in elderly patients supported for cancer.

The objective of the PREDOMOS study is to evaluate the impact of establishing a Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance (PS-DR) on the improvement of quality of life of elderly patients, isolated or at risk of isolation, treated for locally advanced or metastatic cancer.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

320

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 70 years
  • G8 score ≤ 14.
  • WHO score ≤2
  • Having an ADL score ≥ 4 (Katz scale).
  • Having an MMSE score > 24
  • At risk of social isolation: m-MOS below 80%, and / or the following criteria: patient living alone without close help (<50 km) and / or primary caregiver of the patient's spouse, spouse limited autonomy and / or reached itself a disease (neurodegenerative disease, cancer disease, other) requiring regular hospital treatment for at least 3 months.
  • Locally advanced or metastatic cancer or malignant blood disease (except acute leukemia)
  • Treated by chemotherapy, new generation hormone therapy, immunotherapy or targeted therapy in first or second line of treatment, with or without radiotherapy
  • Life expectancy more than 6 months
  • Informed consent signed.
  • Patients affiliated to French social security system in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public Health)

Exclusion Criteria:

  • Patients with other cancers
  • Patients should be directed immediately into a rehabilitation and recuperative care service to receive treatment or in a palliative care service
  • Inability to sign a consent or under guardianship

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Interventional arm PS-DR
The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
Ingen indgriben: Reference Arm
In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Measure of the quality of life by EORTC-QLQc30 scale 3 months after treatment start
Tidsramme: 3 months
The "global health" score will constitute the main judgment criteria
3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to failure of first line of treatment
Tidsramme: From date of inclusion until treatment failure, up to 6 months
Time between inclusion and treatment failure, whatever the cause
From date of inclusion until treatment failure, up to 6 months
First line of treatment toxicity at the end
Tidsramme: 12 months
Measured by Toxicity scale NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events, version 4.0).
12 months
Assessment of the number of chemotherapies received by patient compared to the number of prescribed chemotherapies
Tidsramme: 12 months
Treatment compliance
12 months
Assessment of the patient dependency level determined by evaluating the Daily living activities (ADL) with the Katz scale
Tidsramme: 3 months and 6 months
3 months and 6 months
Assessment of the patient dependency level determined by evaluating the- instrumental activities across Lawton scale
Tidsramme: 3 months and 6 months
3 months and 6 months
Nutritional assessment at 3 months and 6 months
Tidsramme: 3 months and 6 months
Body mass index (BMI) is the ratio of weight to height in cm squared.
3 months and 6 months
Functional assessment at 3 months and 6 months
Tidsramme: 3 months and 6 months
The unipodal station is to stand on one foot without aid. A unipodal station less than 5 seconds indicating a high risk of falls (46).
3 months and 6 months
Overall Survival defined as the time between chemotherapy start and death
Tidsramme: up to 12 months
will be assessed at 6 months and 1 year
up to 12 months
Progression free Survival defined as the time between treatment start and the date of first documented progression or death, whatever the cause.
Tidsramme: up to 12 months

Time to progression is the time elapsed between the date of treatment start and the occurrence of progression or relapse if a response was observed (response or stabilization).

A patient who has not progressed or who did not die at the limit of 1 year will have its censored survival time when tumor enough last evaluation conducted by the deadline of 1 year . The progress will then be defined according to the criteria RECIST1.1 .

In case of death , it will be identified if it is related to tumor progression , toxicity or complication of treatment or another cause (non-specific death).

up to 12 months
Social isolation
Tidsramme: 12 months
Social isolation will be measured by the m -MOS questionnaire. A result < 80% is recognized as the consensus inferior value below which patients are socially isolated position
12 months
Measure of the "global health score" to assess the quality of life at first line of treatment
Tidsramme: 3 months and 6 months
3 months and 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. februar 2018

Primær færdiggørelse (Forventet)

1. august 2021

Studieafslutning (Forventet)

1. august 2022

Datoer for studieregistrering

Først indsendt

29. juni 2016

Først indsendt, der opfyldte QC-kriterier

7. juli 2016

Først opslået (Skøn)

12. juli 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

27. november 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. november 2018

Sidst verificeret

1. november 2018

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2015-44
  • 2015-A01976-43 (Anden identifikator: ANSM)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance

3
Abonner